Departments of Ophthalmology (LSP, MPA, ACP), Pathology (LXS), and Statistics (EA), Universidade Federal de Goiás, Goiânia, Brazil; and The Wilmer Eye Institute (TJM), Johns Hopkins University, Baltimore, Maryland.
J Neuroophthalmol. 2018 Dec;38(4):561-565. doi: 10.1097/WNO.0000000000000639.
The management of nonarteritic anterior ischemic optic neuropathy centers around prevention of second eye involvement, without a uniformly accepted therapy for the involved eye. Several researchers have assessed the benefit of steroids with conflicting results. This experimental study was designed to evaluate the efficacy of a single intravitreal triamcinolone acetonide injection (IVTA) in preserving retinal ganglion cells (RGCs) in a rodent model of anterior ischemic optic neuropathy (rAION).
The rAION was induced in female Wistar rats. Animals were randomized into 3 groups: 1) untreated, 2) treated with 56 μg IVTA, and 3) intravitreal saline (placebo). Procedures were performed in the left eye, with the right eye serving as control. After 30 days, animals were sacrificed and eyes were assessed histologically for RGC number.
The average number of RGC was significantly lower in rAION subgroups when compared with the control group (P < 0.001). No significant difference was seen between rAION eyes treated with IVTA, placebo, and untreated eyes (P > 0.05%).
In this rodent model for AION, no therapeutic benefit of intravitreal steroid injection was identified.
非动脉炎性前部缺血性视神经病变的治疗重点在于预防第二只眼受累，但对于已受累的眼睛，尚无被普遍接受的治疗方法。一些研究人员评估了类固醇的疗效，但结果存在差异。本实验研究旨在评估单次玻璃体内曲安奈德注射（IVTA）在保护前部缺血性视神经病变（rAION）啮齿动物模型中的视网膜神经节细胞（RGC）的疗效。
雌性 Wistar 大鼠诱导 rAION。动物随机分为 3 组：1）未治疗组，2）56μg IVTA 治疗组，3）玻璃体内生理盐水（安慰剂）组。左眼进行手术，右眼作为对照。30 天后，处死动物，对 RGC 数量进行组织学评估。
与对照组相比，rAION 亚组的平均 RGC 数量明显降低（P<0.001）。IVTA 治疗、安慰剂治疗和未治疗的 rAION 眼之间未见显著差异（P>0.05%）。
在该 AION 啮齿动物模型中，玻璃体内类固醇注射没有显示出治疗益处。
